These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 19236135

  • 1. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM.
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [Abstract] [Full Text] [Related]

  • 2. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT, Arfstrom RJ, Mihalovic SW, Dababneh AS, Varatharaj Palraj BR, Dierkhising RA, Mara KC, Lessard SR.
    Am J Ther; 2020 Mar; 27(2):e177-e182. PubMed ID: 30418221
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A.
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
    Reeves SD, Hartmann AP, Tedder AC, Juang PA, Hofer M, Kollef MH, Micek ST, Betthauser KD.
    Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Review of the Resistance Mechanisms for β-Lactams, Macrolides and Fluoroquinolones among Streptococcus pneumoniae.
    Zahari NIN, Engku Abd Rahman ENS, Irekeola AA, Ahmed N, Rabaan AA, Alotaibi J, Alqahtani SA, Halawi MY, Alamri IA, Almogbel MS, Alfaraj AH, Ibrahim FA, Almaghaslah M, Alissa M, Yean CY.
    Medicina (Kaunas); 2023 Oct 31; 59(11):. PubMed ID: 38003976
    [Abstract] [Full Text] [Related]

  • 10. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ, CAP-START Study Group.
    N Engl J Med; 2015 Apr 02; 372(14):1312-23. PubMed ID: 25830421
    [Abstract] [Full Text] [Related]

  • 11. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ, Arnold C, Bassetti S.
    Swiss Med Wkly; 2013 Apr 02; 143():w13870. PubMed ID: 24089030
    [Abstract] [Full Text] [Related]

  • 12. How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.
    Arnold FW.
    Drugs Aging; 2017 Jan 02; 34(1):13-20. PubMed ID: 27928779
    [Abstract] [Full Text] [Related]

  • 13. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D, Gillani SW, Al-Salloum J, Moosvi A, Eissa M, Gulam SM.
    Curr Pediatr Rev; 2020 Jan 02; 16(4):307-313. PubMed ID: 32895041
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR, Lemonovich TL.
    Am Fam Physician; 2011 Jun 01; 83(11):1299-306. PubMed ID: 21661712
    [Abstract] [Full Text] [Related]

  • 15. Appropriate outpatient macrolide use in community-acquired pneumonia.
    Gotfried MH.
    J Am Acad Nurse Pract; 2004 Apr 01; 16(4):146, 148, 150 passim. PubMed ID: 15137473
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S.
    J Infect; 2009 Sep 01; 59(3):222-4. PubMed ID: 19592113
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.